Reformatus Pulmonologiai Centrum — Clinical Trial Site

62 Registered trials

22 Currently recruiting

Organisation

Reformatus Pulmonologiai Centrum

Location

Torokbalint, Hungary

Identifier

ORG-100044167

Address

Munkacsy Mihaly Utca 70, 2045, Hungary

Departments

-
3301:Onkológia Osztály
3302:Onkológia, kúra - fekvőbeteg ellátás
36001: Onkológiai Osztály
4702: NA
5902
Alvasdiagnosztikai Kozpont
Department II.
Department VI. (Felnőtt aktív tüdőgyógyászat)
Gyormektudogyogyaszati Osztaly
III. Osztály
n/a
NA
Not applicable
Oncology
Onko-pulmonológiai és Járóbeteg centrum
Onko-pulmonologiai es jarobetegellato Centrum
Onkologiai Ambulancia
Onkológiai kúra,- fekvőbeteg ellátás
Onkológiai Osztály
Onkológiai Osztály és Kúraszerű Ellátás
Onkopulmonológiai és Járóbeteg centrum
Onkopulmonológiai Járóbeteg Centrum
Reformed Pulmonology Center
Tüdőgyógyászati Szakrendelés
Tudogyogyintezet
VI. Osztaly
VI. osztaly, Onkologia
VI. Tüdőgyógyászati Osztály

Clinical trials at this site (62)

Search interface

Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Locally advanced or metastatic KRAS G12C-mutated non-sm 4 2022-12-06
Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non… Halted

2023-510082-10-00 Advanced non-small cell lung cancer harboring the KRAS 5 2022-09-05
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
Phase 2 First-Line ES-SCLC Platform Study Ended

2023-506538-56-00 First-line treatment of participants with extensive-sta 4 2021-08-12
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-510175-60-00 Chronic obstructive pulmonary disease (COPD) and Chron 5 2021-06-16
A study of MK7684A versus Pembrolizumab in PD-L1 Positive Metastatic NSCLC (KEYVIBE-003) Ended

2023-505362-28-00 Stage IV non small-cell lung cancer 5 2021-04-21
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Lung Cancer, Non-Small Cell 5 2020-12-18
A study to test the efficacy and safety of Lazertinib in the treatment of patients with Locally Advanced or Metastatic Non-Small Cell Lung C… Ended

2024-514771-18-00 Adenocarcinoma of the lung (non-small cell lung cancer) 5 2020-12-15
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel… Ended

2022-502480-38-00 Non−small cell lung cancer (NSCLC) 5 2020-09-09
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended

2022-503050-39-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 5 2019-11-12
Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended

2022-501439-18-00 NSCLC with squamous or nonsquamous histology 5 2019-06-26
Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended

2022-500413-11-00 Unresected Stage I or II Non-Small Cell Lung Cancer (NS 5 2019-06-17